ArticleCell biochemistry and biophysics2026
METTL3-Mediated m6A Modification of ACTR2 Promotes Trophoblast Cell Growth, Migration and Invasion in Unexplained Recurrent Spontaneous Abortion.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actin-related protein 2 (ACTR2) is an important factor in the regulation of cell function and is considered to be a potential therapeutic target for RSA. However, whether ACTR2 mediates unexplained RSA by regulating trophoblast cell function remains unclear. The expression of ACTR2 and methyltransferase-like 3 (METTL3) in the villous tissues of unexplained RSA patients and trophoblast cells (HTR-8/SVneo) was detected by qRT-PCR or western blot. Cell proliferation, apoptosis, invasion, and migration were examined by CCK8 assay, EdU assay, flow cytometry, transwell assay and wound healing assay. MeRIP assay, RIP assay or RNA pull-down assay was used to confirm the interaction between METTL3/YTHDF2 and ACTR2. The regulation of METTL3/YTHDF2 on the mRNA stability of ACTR2 was confirmed by actinomycin D assay. β-catenin and Wnt3A protein levels were tested by western blot. ACTR2 was downregulated in unexplained RSA patients, and its overexpression promoted HTR-8/SVneo cell proliferation, migration, invasion and reduced apoptosis. However, ACTR2 knockdown suppressed HTR-8/SVneo cell functions. ACTR2 had m6A modification sites, and METTL3 could enhance the m6A modification of ACTR2 to reduce its mRNA stability and expression. METTL3-mediated the m6A modification of ACTR2 could be recognized by m6A reader YTHDF2. METTL3 knockdown increased HTR-8/SVneo cell growth, migration and invasion, as well as β-catenin and Wnt3A protein levels, while these effects could be reversed by ACTR2 silencing. METTL3 might inhibit trophoblast cell functions by inactivating Wnt/β-catenin pathway through enhancing the m6A modification of ACTR2, providing a novel target for unexplained RSA.
Indexed as
Identifiers
42631821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.